Kallikrein

Kallikrein Related Products (36):

By Effects:	Substrates (2) Inhibitors (28) Activator (1)

Cat. No.	Product Name	Effect	Purity

HY-16735

Avoralstat	Inhibitor	98.0%
Avoralstat (BCX4161), a potent and orally active plasma kallikrein (PKK) inhibitor, is used for hereditary angioedema research.

HY-P99110

Lanadelumab	Inhibitor	99.74%
Lanadelumab (SHP643) is a human IgG1 monoclonal antibody against plasma kallikrein (pKal) with an K_i value of 0.12 nM. Lanadelumab inhibits both free and HMWK (high molecular weight kininogen)-bound pKal. Lanadelumab has the potential for the research of hereditary angioedema.

HY-148949

Kallikrein 5-IN-2		99.46%
Kallikrein 5-IN-2 (compound 21) is a selective Kallikrein KLK5 inhibitor (pIC₅₀=7.1). KLK5 inhibition may normalise epidermal shedding and reduce the associated inflammation and itching.

HY-132830

Sebetralstat	Inhibitor	99.58%
Sebetralstat (KVD900) is a plasma kallikrein inhibitor (WO2016083820). Sebetralstat can be used for the research of metabolic diseases.

HY-P4245

D-Pro-Phe-Arg-Chloromethylketone	Inhibitor	99.24%
D-Pro-Phe-Arg-Chloromethylketone, a inhibitor of coagulation factor XII and plasma kallikrein, plays an important role in thrombosis and inflammation.

HY-P991676

Eflumenibep alfa	Inhibitor
Eflumenibep alfa is a Kallikrein 5 inhibitor with anti-inflammatory activity. Eflumenibep alfa is a fusion protein that combines human SPINK2 with the human IgG1 Fc fragment at the C-terminus.

HY-117478

FE-999024	Inhibitor
FE-999024 (CH-2856) is a specific tissue kallikrein inhibitor. FE-999024 can inhibit cancer cells invasion with a maximum of 39%. FE-999024 can reduce eosinophilia in a model of allergic inflammation. FE-999024 can be used for the research of cancer, inflammation and immunology.

HY-177652A

Onvuzosiran sodium	Inhibitor
Onvuzosiran sodium, a siRNA, is a prekallikrein synthesis reducer.

HY-109127

Berotralstat	Inhibitor	99.70%
Berotralstat (BCX7353) is an orally active plasma kallikrein inhibitor. Berotralstat can reduce brain edema and is being studied for glioblastoma and hereditary angioedema.

HY-108814A

Ecallantide TFA	Inhibitor	98.94%
Ecallantide (DX-88) TFA is a specific recombinant plasma kallikrein inhibitor. Ecallantide inhibits the production of bradykinin. Ecallantide may be used to prevent acute attacks of angioedema.

HY-123133

PKSI-527	Inhibitor	98.08%
PKSI-527 is a new, highly selective plasma kallikrein inhibitor. PKSI-527 can suppress collagen-induced arthritis (CIA) by modifying the kallikrein-kinin system.

HY-109127A

Berotralstat dihydrochloride	Inhibitor	98.49%
Berotralstat dihydrochloride (BCX7353 dihydrochloride) is an orally active plasma kallikrein inhibitor. Berotralstat can reduce brain edema and is being studied for glioblastoma and hereditary angioedema.

HY-P0237A

KKI-5 TFA		98.74%
KKI-5 (TFA) is a specific inhibitor of tissue kallikrein. KKI-5 (TFA) can attenuate breast cancer cell invasion.

HY-145568

Feniralstat	Inhibitor	99.12%
Feniralstat (compound 30), a pyrazole derivative, is a potent kallikrein inhibitor with an IC₅₀ of 6.7 nM for Human plasma kallikrein (pKal). Feniralstat has no inhibition on Human KLKl, Human FXIa, Human Factor Xlla (all IC₅₀>40 μM).

HY-153115

Plasma kallikrein-IN-4	Inhibitor	98.61%
Plasma kallikrein-IN-4 (Example 153) is a plasma kallikrein inhibitor with an IC₅₀ of 0.016 μM against human plasma kallikrein.

HY-122543

PPACK II diTFA	Inhibitor
PPACK II diTFA is an irreversible and specific glandular and plasma kallikreins inhibitor.

HY-114150D

D-Val-Leu-Arg-pNA acetate		99.75%
D-Val-Leu-Arg-pNA (acetate) is the acetate form of D-Pro-Phe-Arg-p-nitroanilide (pNa). D-Pro-Phe-Arg-p-nitroanilide (pNa) is the substrate for kallikrein and can be used to assay the activity of kallikrein.

HY-126378

LSP-249	Inhibitor	99.05%
LSP-249 (example 35), extracted from patent WO2016011209A1, is a plasma kallikrein inhibitor under the study for angioedema, with an EC₅₀ less than 100 nM in cell.

HY-139888

Plasma kallikrein-IN-1	Inhibitor
Plasma kallikrein-IN-1 is a PKK inhibitor with an IC₅₀ value of 0.5 nM.

HY-11090A

DPC423	Inhibitor
DPC423 is a selective and orally active factor Xa inhibitor with a K_is of 0.15 (human) and 0.3 (rabbit) nM. DPC423 exhibits K_is of 60, 61 and 6000 nM against human trypsin, plasma kallikrein and thrombin. DPC423 blocks the formation of prothrombinase complex, reduces thrombin production, inhibits fibrin formation and platelet activation. DPC423 has demonstrated antithrombotic effects in animal models, and when used in combination with Aspirin (HY-14654), it shows a strong synergistic effect. DPC423 can be used for the study of anticoagulation of arterial thrombosis.

Name
Email *

	Sorry, but the email address you supplied was invalid.